Northland Securities analyst Jason Wittes maintained a Buy rating on NovoCure (NASDAQ:NVCR) Ltd on Wednesday, setting a price target of $200, which is approximately 18.37% above the present share price of $168.96.
Wittes expects NovoCure Ltd to post earnings per share (EPS) of $0.09 for the fourth quarter of 2020.
The current consensus among 5 TipRanks analysts is for a Moderate Buy rating of shares in NovoCure, with an average price target of $163.33.
The analysts price targets range from a high of $200 to a low of $140.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $132.66 million and a net profit of $15.02 million. The company's market cap is $17.38 billion.
According to TipRanks.com, Northland Securities analyst Jason Wittes is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 14.3% and a 61.84% success rate.
NovoCure Ltd. develops treatment for tumors. Its platform is called the Tumor Treating Field which used electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.